AOD-9604
Lipolytic hGH Fragment & Fat Metabolism Regulation
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal fragment of human growth hormone, corresponding to the hGH(176-191) region. It was developed to isolate the fat-metabolizing portion of the growth hormone molecule while omitting the sequences responsible for growth promotion and effects on insulin sensitivity. In preclinical models, AOD-9604 has been studied primarily for its role in lipid metabolism: research suggests it stimulates lipolysis (the breakdown of stored fat) and inhibits lipogenesis (the formation of new fat), with proposed involvement of beta-3-adrenergic receptor signaling in adipose tissue.
A distinguishing feature reported in the research literature is that AOD-9604 appears to influence fat metabolism without the broader growth-promoting activity of full-length hGH. Preclinical studies indicate it does not meaningfully raise IGF-1 levels or stimulate growth-plate activity, and it has not been shown to affect blood glucose in the way that full growth hormone can. This selectivity is the central reason the fragment has attracted interest as a metabolic research compound. Earlier clinical investigation of AOD-9604 explored applications such as obesity and joint-related conditions, but the results in humans have been mixed and it has not been established as an approved therapeutic.
Overall, the evidence base for AOD-9604 is more preliminary than that of the incretin-based metabolic peptides, and much of the supporting data comes from animal and cell studies rather than large human trials. Its lipolytic mechanism remains an area of continued investigation, and firm conclusions about efficacy in humans cannot be drawn from the current literature. AOD-9604 as offered here is a research peptide provided strictly for research and educational purposes only — it is not approved for human use, and nothing on this page should be construed as medical advice or a health claim.
Molecular data
Mechanism of action
In preclinical research, AOD-9604 is associated with the following pathways and targets:
Research highlights
- Stimulates lipolysis via β3-adrenergic receptor pathway
- Inhibits lipogenesis without affecting blood glucose
- Derived from hGH C-terminal fragment (176-191)
- No effect on IGF-1 levels or growth plate stimulation
Frequently asked questions
What does AOD-9604 do?
AOD-9604 is a fragment of human growth hormone studied for fat metabolism. Preclinical research suggests it stimulates lipolysis and inhibits lipogenesis, potentially via beta-3-adrenergic signaling, without the growth-promoting effects of full-length hGH.
What is AOD-9604 derived from?
It is a synthetic 16-amino-acid fragment corresponding to the C-terminal hGH(176-191) region of human growth hormone, designed to isolate fat-metabolizing activity while omitting growth-promoting sequences.
Does AOD-9604 affect IGF-1 or blood glucose?
Preclinical research indicates AOD-9604 does not meaningfully raise IGF-1 levels or stimulate growth-plate activity, and it has not been shown to affect blood glucose the way full-length growth hormone can.
Is AOD-9604 an approved weight-loss drug?
No. Earlier clinical studies explored obesity and joint applications with mixed results, and it is not an approved therapeutic. The AOD-9604 sold here is a research peptide for laboratory use only.
How is AOD-9604 different from GLP-1 peptides?
AOD-9604 is an hGH fragment studied for direct effects on fat metabolism, whereas GLP-1 class peptides are incretin receptor agonists that act on insulin, glucagon, and appetite pathways. Their mechanisms and evidence bases differ substantially.
Source AOD-9604 at Purgo Labs
≥99% purity, third-party COA verification, and same-day fulfillment.
Shop AOD-9604 at Purgo Labs ↗Related compounds
For research and educational purposes only. AOD-9604 is not approved for human use by any regulatory authority, and nothing on this page constitutes medical advice, diagnosis, or treatment. Research findings referenced here are predominantly preclinical.